Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfolio

Third Arc Bio宣布完成5200万美元A轮融资扩展，以扩大其肿瘤学、免疫学和炎症领域的产品组合。

$52M equity adds to previously announced $165M Series A

5200万美元的股权融资增加了此前宣布的1.65亿美元A轮融资

New investor Andreessen Horowitz (a16z) leads the financing with founding investor Omega Funds; additional investors include Life Sciences at Goldman Sachs Alternatives, BVF Partners LP, funds managed by abrdn. Inc., accounts advised by T. Rowe Price Associates, Inc., Marshall Wace, Hillhouse Investment, Galapagos NV, AbbVie Ventures, and Alderline Group.

新投资者 Andreessen Horowitz (a16z) 与创始投资者 Omega Funds 共同领投融资，其他投资者包括高盛另类投资集团旗下的生命科学部门、BVF Partners LP、由 abrdn. Inc. 管理的基金、T. Rowe Price Associates, Inc. 建议的账户、Marshall Wace、高瓴投资、Galapagos NV、AbbVie Ventures 和 Alderline Group。

SPRING HOUSE, Pa., February 4, 2026-- Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, today announced the closing of a $52 million Series A extension.

宾夕法尼亚州斯普林豪斯，2026年2月4日——Third Arc Bio Inc.是一家处于临床阶段的生物技术公司，致力于开发用于多种肿瘤学及免疫学与炎症（I&I）适应症的新型多功能抗体，该公司今日宣布完成了5200万美元的A轮融资扩展。

New investor Andreessen Horowitz (a16z) joined Third Arc Bio's existing world-class investor syndicate to further validate the company's approach to deliver transformational therapies for patients. As part of the financing, a16z General Partner, Jorge Conde, joins Third Arc Bio's Board of Directors.

新投资者 Andreessen Horowitz (a16z) 加入了 Third Arc Bio 现有的世界级投资者财团，进一步验证了该公司为患者提供变革性疗法的方法。作为融资的一部分，a16z 普通合伙人 Jorge Conde 加入了 Third Arc Bio 董事会。

Proceeds from the financing will enable Third Arc Bio to accelerate its I&I portfolio and deliver additional oncology programs into the clinic..

融资所得将使 Third Arc Bio 能够加速其 I&I 产品组合，并将更多的肿瘤学项目引入临床。

'Third Arc represents a shift toward more precise immune modulation—moving beyond systemic exposure to therapies designed to deliver highly controlled biological effects at sites of disease,' said Jorge Conde, General Partner at a16z. 'The company's platforms, combined with a team that has repeatedly translated complex immunology into approved medicines, reflect a rigorous, patient-driven approach to building biologics that can improve both efficacy and safety across oncology and immune-mediated disease.'.

“第三弧线代表了向更精确的免疫调节转变——超越系统性暴露，转向旨在疾病部位产生高度可控生物学效应的疗法，”a16z的普通合伙人豪尔赫·孔德表示。“该公司的平台，加上一个多次将复杂免疫学转化为获批药物的团队，体现了一种严谨、以患者为中心的方法，以构建能够提高肿瘤学和免疫介导疾病中疗效和安全性的生物制品。”

Since its launch in 2022 with seed financing from Omega Funds, Third Arc Bio has assembled a highly experienced team with a proven track record of drug discovery and development, alongside an innovative platform and a pipeline of multispecific antibodies. The company's lead asset, ARC101, is a bispecific T cell engager targeting CLDN6 currently in Phase 1 dose escalation in patients with advanced solid tumors..

自2022年在Omega Funds的种子融资支持下推出以来，Third Arc Bio组建了一支经验丰富的团队，他们在药物发现和开发方面有着可靠的成功记录，同时拥有一个创新平台及多特异性抗体的研发管线。该公司的主要资产ARC101是一种双特异性T细胞衔接器，靶向CLDN6，目前正在进行针对晚期实体瘤患者的1期剂量递增试验。

'This financing allows us to maintain momentum across our expanding oncology portfolio while rapidly advancing our next-generation I&I assets into first-in-human studies,' said Peter F. Lebowitz, MD, PhD, Chief Executive Officer of Third Arc Bio. 'By parallel-tracking programs, we can more efficiently validate the full potential of our platforms, rapidly generate proof-of-concept data, and deliver innovative therapies for patients with significant unmet need.'.

“这笔融资使我们能够在不断扩展的肿瘤学产品组合中保持发展势头，同时迅速将我们的下一代I&I资产推进到首次人体研究，” Third Arc Bio首席执行官Peter F. Lebowitz医学博士表示，“通过并行跟踪项目，我们能够更高效地验证平台的全部潜力，快速生成概念验证数据，并为存在显著未满足需求的患者提供创新疗法。”

Third Arc Bio's approach to I&I is anchored by its ARCTag (Tethered Agonist) Platform, which leverages multispecific antibodies to localize immune modulation directly to sites of disease. This targeted activity represents a meaningful advance beyond conventional systemic autoimmune therapies, offering the potential for enhanced efficacy and therapeutic index..

第三弧生物公司针对I&I的方法依托于其ARCTag（栓系激动剂）平台，该平台利用多特异性抗体将免疫调节直接定位于疾病部位。这种针对性的活性代表了对传统系统性自身免疫疗法的重大进步，具有提高疗效和治疗指数的潜力。

About Third Arc Bio

关于第三弧生物

Third Arc Bio is a clinical stage biotech company developing multifunctional antibodies that generate immune synapses to precisely activate or inhibit T cells. The lead program ARC101, is a bispecific T cell engager currently being evaluated in a Phase 1 trial for cancer patients with solid tumors expressing CLDN6.

第三弧生物是一家临床阶段的生物技术公司，正在开发多功能抗体，这些抗体生成免疫突触以精确激活或抑制T细胞。其主要项目ARC101是一种双特异性T细胞衔接器，目前正在进行一项针对表达CLDN6的实体瘤癌症患者的1期试验评估。

The company's drug development engine delivers superior biologics optimized to create best-in-class T cell engagement by leveraging novel technologies that power a pipeline of high value therapeutics. The Third Arc Bio platforms include a solid tumor ARCStim Platform and an immunology & inflammation (I&I) ARCTag Platform that offers precision immune regulation to achieve superior efficacy and safety.

该公司药物开发引擎提供经过优化的卓越生物制品，通过利用推动高价值治疗管道的新型技术，实现同类最佳的T细胞参与。Third Arc Bio平台包括实体瘤ARCStim平台和免疫学与炎症（I&I）ARCTag平台，后者提供精准的免疫调节，以实现卓越的疗效和安全性。

To learn more, visit www.thirdarcbio.com..

要了解更多信息，请访问 www.thirdarcbio.com。

Contact:

联系人：

Media Contact

媒体联系人

Peg Rusconi, Deerfield Group

佩格·鲁斯科尼，迪尔菲尔德集团

peg.rusconi@deerfieldgroup.com

佩格·鲁斯科尼@迪尔菲尔德集团.com